Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25342137 | 0.98 | BLM (0.41) | TSHRSLC6A1SLC6A13CHRM3BLM | |
| SCHEMBL22141947 | 0.86 | — | — | |
| SCHEMBL18134378 | 0.79 | HTR2C (0.31) | HTR2C | |
| SCHEMBL22648489 | 0.79 | CHRM2 (0.35) | TSHRSLC6A1SLC6A13CHRM3BLM | |
| SCHEMBL22142076 | 0.77 | CHRM2 (0.34) | TSHRSLC6A1SLC6A13CHRM3BLM | |
| SCHEMBL22488553 | 0.76 | TSHR (0.39) | TSHRSLC6A1SLC6A13CHRM3BLM | |
| SCHEMBL10050843 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL22468585 | 0.74 | BLM (0.41) | TSHRSLC6A1SLC6A13CHRM3BLM | |
| SCHEMBL22142094 | 0.72 | CHRM2 (0.37) | TSHRSLC6A1SLC6A13CHRM3CHRM2 | |
| SCHEMBL22142077 | 0.72 | CHRM2 (0.37) | TSHRSLC6A1SLC6A13CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472968-A1 | INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2024-12-11 | — | — | EP | disclosed |
| CN-118974036-A | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-21 | — | — | US | disclosed |
| US-9938294-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-9624241-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624241-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-9227985-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | TSHR 1226/4885SLC6A1 4872/4885SLC6A13 4881/4885 |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TSHR 1769/4885SLC6A1 4480/4885SLC6A13 4511/4885 |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TSHR 1771/4885SLC6A1 4579/4885SLC6A13 4700/4885 |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | TSHR 1226/4885SLC6A1 4872/4885SLC6A13 4881/4885 |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | MYLK2, MYOF, MUSK | TSHR 2411/4885SLC6A1 325/4885SLC6A13 491/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TSHR 1769/4885SLC6A1 4480/4885SLC6A13 4511/4885 |
| US-10654828-B2 | Indole derivatives and uses thereof | MYLK2, MYOF, MUSK | TSHR 2411/4885SLC6A1 325/4885SLC6A13 491/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | TSHR 719/4885SLC6A1 4800/4885SLC6A13 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.